Setrusumab Phase 2/3 study in osteogenesis imperfecta

Phase 3, randomised, double-blind trial of setrusumab in osteogenesis imperfecta (OI) (4 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Percent change in serum P1NP from baseline at Month 1 and Annualized rate of radiographically confirmed fractures excluding morphometric vertebral fractures and fractures of the fingers, toes, face, and skull. Planned start May 2023; status: authorised.